報價延遲最少15分鐘:2025/07/21 06:57 EDT
盤前時段
|
||||
|
8.03 
|
|
|
常規時段
|
|
|
|
|
||||||||||||
|
|
|
|
|
7.95
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-5.18/-0.62
|
|
企業價值
782.26M
|
| 資產負債 |
|
每股賬面淨值
-4.85
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
55.25M
|
|
每股收益
--
|
|
同行比較
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
報價延遲最少15分鐘：2025/07/21 06:57 EDT
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection. |
